General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Drug discovery and development process

Novartis drug discovery and development efforts begin and end with the patient. Our R&D efforts are guided by two principles:

  • Do we understand the underlying mechanism or cause of the disease?
  • Does this disease represent a significant unmet medical need in patients?

If the answer to both questions is "yes," then we develop a research program aimed at better understanding the disease and finding an effective chemical or biologic based medicine.